LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF7 | A443654 | 3.33 | uM | LJP6 | 72 | hr | 1209 | 636 | 4093 | 0.1554 | -0.1989 |
MCF7 | OSI-027 | 3.33 | uM | LJP6 | 72 | hr | 1209 | 1459 | 4093 | 0.3565 | 0.0865 |
MCF7 | XMD11-85h | 3.33 | uM | LJP6 | 72 | hr | 1209 | 3452 | 4093 | 0.8435 | 0.7778 |
MCF7 | HG-6-64-01 | 3.33 | uM | LJP6 | 72 | hr | 1209 | 3307 | 4093 | 0.8081 | 0.7275 |
MCF7 | WH-4-025 | 3.33 | uM | LJP5 | 72 | hr | 1209 | 2001 | 4093 | 0.4889 | 0.2745 |
MCF7 | WZ-4-145 | 3.33 | uM | LJP6 | 72 | hr | 1209 | 1357 | 4093 | 0.3316 | 0.0513 |
MCF7 | XMD16-144 | 3.33 | uM | LJP5 | 72 | hr | 1209 | 1457 | 4093 | 0.3561 | 0.0859 |
MCF7 | Brivanib | 3.33 | uM | LJP5 | 72 | hr | 1209 | 4047 | 4093 | 0.9889 | 0.9843 |
MCF7 | Buparlisib | 3.33 | uM | LJP5 | 72 | hr | 1209 | 838 | 4093 | 0.2048 | -0.1287 |
MCF7 | BX-912 | 3.33 | uM | LJP5 | 72 | hr | 1209 | 1766 | 4093 | 0.4316 | 0.1931 |
MCF7 | Canertinib | 3.33 | uM | LJP6 | 72 | hr | 1209 | 2633 | 4093 | 0.6435 | 0.4939 |
MCF7 | Celastrol | 3.33 | uM | LJP6 | 72 | hr | 1209 | 1009 | 4093 | 0.2465 | -0.0696 |
MCF7 | CGP60474 | 3.33 | uM | LJP5 | 72 | hr | 1209 | 642 | 4093 | 0.1569 | -0.1967 |
MCF7 | CGP60474 | 3.33 | uM | LJP6 | 72 | hr | 1209 | 707 | 4093 | 0.1727 | -0.1743 |
MCF7 | CHIR-99021 | 3.33 | uM | LJP6 | 72 | hr | 1209 | 3034 | 4093 | 0.7414 | 0.6329 |
MCF7 | CP724714 | 3.33 | uM | LJP5 | 72 | hr | 1209 | 3762 | 4093 | 0.9193 | 0.8854 |
MCF7 | CP466722 | 3.33 | uM | LJP5 | 72 | hr | 1209 | 3332 | 4093 | 0.8142 | 0.7362 |
MCF7 | Crizotinib | 3.33 | uM | LJP5 | 72 | hr | 1209 | 1299 | 4093 | 0.3174 | 0.0310 |
MCF7 | Momelotinib | 3.33 | uM | LJP5 | 72 | hr | 1209 | 1704 | 4093 | 0.4163 | 0.1715 |
MCF7 | Dasatinib | 3.33 | uM | LJP5 | 72 | hr | 1209 | 1616 | 4093 | 0.3948 | 0.1410 |
MCF7 | Dasatinib | 3.33 | uM | LJP6 | 72 | hr | 1209 | 1545 | 4093 | 0.3775 | 0.1163 |
MCF7 | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 1209 | 1690 | 4093 | 0.4130 | 0.1667 |
MCF7 | Enzastaurin | 3.33 | uM | LJP5 | 72 | hr | 1209 | 3917 | 4093 | 0.9571 | 0.9391 |
MCF7 | Erlotinib | 3.33 | uM | LJP5 | 72 | hr | 1209 | 4251 | 4093 | 1.0386 | 1.0548 |
MCF7 | Foretinib | 3.33 | uM | LJP5 | 72 | hr | 1209 | 1209 | 4093 | 0.2954 | -0.0002 |